P Mollee, K Taylor, C Arthur… - 2nd Annual Scientific …, 2011 - espace.library.uq.edu.au Mollee, P., Taylor, K., Arthur, C., Wright, S. and Morton, J. (2000). A phase II study of interferon alpha (IFN) and intermittent oral cytarabine (YNK01) in the treatment of newly diagnosed chronic myeloid leukemia (CML). In: , Blood: The 2nd Annual Scientific Meeting of the ... Cited by 6 - Related articles - Cached
[HTML] from ascopubs.orgH Inaba, JE Rubnitz, E Coustan-Smith… - Journal of Clinical …, 2011 - jco.ascopubs.org Corresponding author: Hiroto Inaba, MD, PhD, Department of Oncology, St Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105; e-mail: hiroto.inaba{at}stjude.org. ... Presented in part at the 52nd Annual Meeting of the American Society of Hematology, ...
R Nelson - N Engl J Med, 2011 - medscape.com March 16, 2011 — High doses of cytarabine are more effective than conventional doses in inducing relapse-free survival in patients with acute myeloid leukemia (AML). Now, data suggest that an intermediate dose might be just as effective as a high dose, but with less toxicity.
AJM Ferreri, G Licata, M Foppoli, G Corazzelli… - The …, 2011 - AlphaMed Press Abstract Background. The combination of high doses of methotrexate (MTX) and cytarabine (araC) is the standard chemotherapy for patients with primary CNS lymphoma (PCNSL). The addition of an alkylating agent could improve MTX-araC efficacy because it is active ... Cited by 1 - Related articles - All 3 versions
[PDF] from haematologica-thj.orgSH Kaufmann, J Karp, M Litzow, R Mesa… - …, 2011 - haematologica.org Publisher's Disclaimer. E-publishing ahead of print is increasingly important for the rapid dissemination of science. Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that have completed a regular peer review and have been accepted for publication. E- ...
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
安全保密
